INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED
領航醫藥及生物科技有限公司
(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)
(Stock Code: 399)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 29 AUGUST 2025

Reference is made to the circular (the "**Circular**") of Innovative Pharmaceutical Biotech Limited (the "**Company**") and the Notice of the Annual General Meeting dated 31 July 2025 (the "**Notice**"). Unless the context otherwise requires, terms defined in this announcement shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE ANNUAL GENERAL MEETING

The Board is pleased to announce that at the Annual General Meeting held on 29 August 2025, the proposed resolutions as set out in the Notice were duly passed by the Shareholders by way of poll pursuant to Rule 13.39(4) of the Listing Rules.

Tricor Tengis Limited, the Company's branch share registrar, acted as the scrutineer for the purpose of the counting of votes at the Annual General Meeting. The poll results of the resolutions at the Annual General Meeting are as follows:

ORDINARY RESOLUTIONS		For		Against	
		Number of Shares	%	Number of Shares	%
1.	To receive and adopt the audited financial statements and the reports of the directors (the "**Directors**") and of the auditors of the Company for the year ended 31 March 2025.	670,467,440	99.83	1,150,000	0.17

ORDINARY RESOLUTIONS		For		Against	
		Number of Shares	%	Number of Shares	%
2.	(i) To re-elect Dr. Yeung Yung as an executive Director;	671,617,440	100	0	0
	(ii) To re-elect Mr. Gao Yuan Xing as an executive Director;	671,617,440	100	0	0
	(iii) To re-elect Mr. Tang Rong as an executive Director;	671,617,440	100	0	0
	(iv) To re-elect Ms. Qi Shujuan as an executive Director;	671,617,440	100	0	0
	(v) To re-elect Dr Long Fan as an executive Director;	671,617,440	100	0	0
	(vi) To re-elect Dr. Wu Ming as an executive Director;	671,617,440	100	0	0
	(vii) To re-elect Mr. Zhang Shen as an executive Director;	671,617,440	100	0	0
	(viii) To re-elect Mr. Zhang Yi as a non-executive Director;	671,617,440	100	0	0
	(ix) To re-elect Ms. Chen Weijun as an independent non-executive Director;	671,617,440	100	0	0
	(x) To re-elect Dr. Xia Tingkang, Tim as an independent non-executive Director;	671,617,440	100	0	0
	(xi) To re-elect Ms. Sun Sizheng as an independent non-executive Director; and	671,617,440	100	0	0
	(xii) To authorise the board of Directors to fix the Directors' remuneration.	671,617,440	100	0	0
3.	To re-appoint SFAI (HK) CPA Limited as the Company's auditors and to authorise the board of Directors to fix their remuneration.	671,617,440	100	0	0
4.	To give a general mandate to the Directors to allot, issue and otherwise deal with additional Shares not exceeding 20% of the total number of the issued shares of the Company as at the date of this resolution.	670,467,440	99.83	1,150,000	0.17

ORDINARY RESOLUTIONS		For		Against	
		Number of Shares	%	Number of Shares	%
5.	To give a general mandate to the Directors to buy back the Shares not exceeding 10% of the total number of the issued shares of the Company as at the date of this resolution.	671,617,440	100	0	0
6.	To extend the general mandate granted to the Directors to issue the Shares pursuant to the foregoing resolution no. 4 by a total number of Shares bought back by the Company pursuant to the foregoing resolution no. 5.	670,467,440	99.83	1,150,000	0.17
7.	To approve the increase in authorised share capital of the Company from (i) HK$500,000,000 divided into 50,000,000,000 shares of HK$0.01 each to (ii) HK$1,200,000,000 divided into 120,000,000,000 shares of HK$0.01 each, by the creation of an additional 70,000,000,000 shares of HK$0.01 each.	670,467,440	99.83	1,150,000	0.17
SPECIAL RESOLUTION		**For**		**Against**	
		Number of Shares	**%**	**Number of Shares**	**%**
8.	To approve the change in the English name of the Company from "Innovative Pharmaceutical Biotech Limited" to "Starcoin Group Limited", and the Chinese name of "星太鏈集團有限公司" to be adopted as the secondary name of the Company in place of the existing name of "領航醫藥及生物科技有限公司".	671,617,440	100	0	0

The full text of each of the resolutions numbered 1 to 8 above is set out in the Notice.

As more than 50% of the votes were cast in favour of each of the above ordinary resolutions numbered 1 to 7, such resolutions were duly passed by Shareholders by way of poll at the Annual General Meeting. As more than 75% of the votes were cast in favour of the above special resolution, the special resolution numbered 8 above was duly passed as special resolution by way of poll at the Annual General Meeting.

As at the date of the Annual General Meeting, a total of 2,142,787,625 Shares were in issue, which is the total number of Shares held by Shareholders entitled to attend and vote on all the proposed resolutions at the Annual General Meeting. No Shareholder was required under the Listing Rules to abstain from voting at the Annual General Meeting on any of the resolutions proposed thereat. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions proposed at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the Annual General Meeting. As at the date of the Annual General Meeting, there were no treasury shares held by the Company (including any treasury shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited) and no repurchased shares which are pending cancellation and should be excluded from the total number of issued shares for the purpose of the Annual General Meeting. The Company confirms that it did not exercise its voting rights in respect of any treasury shares at the Annual General Meeting.

The directors of the Company, Dr. Yeung Yung, Mr. Gao Yuan Xing, Mr. Tang Rong, Dr. Long Fan, Dr. Wu Ming, Mr. Zhang Shen, Mr. Zhang Yi, Ms. Chen Weijun, and Ms. Sun Sizheng, attended the Annual General Meeting either in person or by electronic means.

By Order of the Board
Innovative Pharmaceutical Biotech Limited
Yeung Yung
Chairman

Hong Kong, 29 August 2025

As at the date of this announcement, the Board comprises, Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director) Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkang, Tim (independent non-executive Director) and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: www.ipb.asia and www.irasia.com/listco/hk/ipb.